论文部分内容阅读
目的:探讨联合检测血清人附睾上皮分泌蛋白4(HE4)和糖类抗原125(CA125)在盆腔恶性肿瘤诊断中的价值。方法:对66例健康体检者、59例盆腔良性肿瘤患者以及50例盆腔恶性肿瘤患者分别采用酶联免疫吸附法和微粒子酶免疫分析技术检测血清HE4和CA125含量并做统计学分析。结果:盆腔恶性肿瘤患者HE4和CA125水平均高于正常对照组和良性病变组。HE4和CA125的联合检测显著提高了盆腔恶性肿瘤诊断效能。结论:HE4的诊断价值与CA125相当,尽管每个标志物各有优缺点,在盆腔恶性肿瘤诊断中联合检测HE4和CA125,优于单个指标检测。
Objective: To investigate the value of combined detection of serum human epididymal epithelial secrection protein 4 (HE4) and carbohydrate antigen 125 (CA125) in the diagnosis of pelvic malignant tumors. Methods: Serum levels of HE4 and CA125 were detected by enzyme-linked immunosorbent assay and microparticle enzyme immunoassay in 66 healthy subjects, 59 patients with pelvic benign tumors and 50 patients with pelvic malignant tumors. Statistical analysis was performed. Results: The levels of HE4 and CA125 in pelvic malignant tumors were significantly higher than those in normal control group and benign lesion group. The combined detection of HE4 and CA125 markedly improved the diagnostic efficacy of pelvic malignancies. CONCLUSIONS: The diagnostic value of HE4 is comparable to that of CA125. Although each marker has its own advantages and disadvantages, the combination of HE4 and CA125 in the diagnosis of pelvic malignancies is superior to single marker detection.